{"ticker": {"uuid": "e5703775-527e-4579-ac4c-1154f11bf512", "symbol": "CSBR", "name": "Champions Oncology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Champions Oncology to announce Q4 and FY26 results on July 27", "summary": "Champions Oncology, Inc. will release its financial and operational results for the quarter and fiscal year ended April 30, 2026, after market close on Monday, July 27, 2026. The company will also host a conference call on the same day at 4:30 P.M. ET to discuss these results. Re", "url": "https://scanx.trade/stock-market-news/companies/champions-oncology-to-announce-q4-and-fy26-results-on-july-27/46126275", "source_name": "scanx.trade", "published_at": "2026-07-21T05:40:09", "published_display": "21 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxNRk1yY2pGbk5JNEhoazNSX20zVjI5aklBQXo4RUFIdDc3ZENGVGxMMlgyX0hXTHROSmpPOE1uVmNqYkw5ekdqSEh5R2U0emZuZ1kwN2lMek9ObENabU1LenhBTFk4a0pZelctbGVzRklQNGFPTjdXcVp3ZE5MU2xna2RPbXg3UjZZanlMQ2tOUDNPQVdCYjVyZGNGa1FSZHNKRHFHa04tUEV3Nm45OWV4MG5GdFdLQVJCd096MVB4eVpfVlFaR1NlMktvcElUb1VZcHkyVFhuZFlNdkhQRWIteEZlMTdZM1A0RHlqTFdpWmVzQ0QwYjFHbUVPcXNhOGtIbXdWSEVscnlmMl83Qk5vMEcwNA?oc=5", "source_name": "Hastings Tribune", "published_at": "2026-07-20T20:32:04+00:00", "published_display": "20 Jul 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Schedules Year-End Results Call for 4:30 p.m.", "summary": "Champions Oncology (NASDAQ: CSBR) announced it will report its financial and operational results for the fourth quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call on the same day at 4:30 P.M. ET to discuss ", "url": "https://www.stocktitan.net/news/CSBR/champions-oncology-to-announce-fourth-quarter-and-year-end-financial-o13dpnuyz99h.html", "source_name": "Stock Titan", "published_at": "2026-07-20T20:40:09", "published_display": "20 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Champions Oncology, Inc. \u2013 SWB:2I3", "summary": "This article from TradingView provides financial information for Champions Oncology, Inc. (SWB:2I3), specifically focusing on its enterprise value to EBITDA forward. It indicates that the company is listed on the Stuttgart Stock Exchange and presents various financial metrics and", "url": "https://www.tradingview.com/symbols/SWB-2I3/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T06:41:04", "published_display": "19 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38 - Volatility Stop", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM09pVEVLa242bmNFQTY3dTd1enc5MlNoRjFnWnlLRUEyYzFFNkZ5bUNKYUtOZU5VdkpWSGY2U1NDRWpVR2dmaEJYWHNya1ZrRGtYNWtWTkM1R3VQTTJuZEJkX3BQYkRadnA3c2xoUHA4ejVhLVpCN2dLTWdvN1hVN2h1V2ZHZFdSRWVFVmVLODU1SU5qRE9GbGY4YUlWYU5qeVBkSHkzQlpPVzJrRWx1dFNR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-15T13:34:38+00:00", "published_display": "15 Jul 2026 13:34", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Champions Oncology, Inc. \u2013 DUS:2I3", "summary": "The article focuses on the \"Enterprise value to EBITDA forward\" metric for Champions Oncology, Inc. (DUS:2I3) listed on the Dusseldorf Stock Exchange. It appears to be a financial data point provided by TradingView, without presenting any specific values or detailed financial ana", "url": "https://www.tradingview.com/symbols/DUS-2I3/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T20:16:52", "published_display": "14 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Champions Oncology, Inc. \u2013 DUS:2I3", "summary": "This article focuses on the enterprise value to EBIT forward for Champions Oncology, Inc. (DUS:2I3) as listed on the Dusseldorf Stock Exchange. It appears to be a financial data point from a trading platform, indicating market closed with no trades. The content primarily lists va", "url": "https://www.tradingview.com/symbols/DUS-2I3/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T22:10:30", "published_display": "13 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (CSBR) Edition", "summary": "This article analyzes Champions Oncology Inc. (NASDAQ: CSBR), highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies\u2014Position", "url": "https://news.stocktradersdaily.com/news_release/39/Trading_the_Move,_Not_the_Narrative:_CSBR_Edition_071326064601_1783982761.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T18:46:00", "published_display": "13 Jul 2026 18:46", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CSBR Q4'25 Earnings: revenue estimate is 12.89M USD", "summary": "Champions Oncology, Inc. (CSBR) is scheduled to release its Q4'25 earnings on July 16, with an estimated revenue of $12.89 million and an anticipated EPS of ($0.05). The article provides a detailed table of past and estimated revenue and EPS figures, highlighting previous surpris", "url": "https://www.tradingview.com/news/tradingview:992cc05abe7d3:0-csbr-q4-25-earnings-revenue-estimate-is-12-89m-usd/", "source_name": "TradingView", "published_at": "2026-07-09T11:12:21", "published_display": "09 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CSBR) Volatility Zones as Tactical Triggers", "summary": "Champions Oncology Inc. (NASDAQ: CSBR) is currently showing near-term weak sentiment, challenging mid-term strength within a broader long-term weak bias, according to an AI analysis. The article outlines three distinct trading strategies\u2014Position Trading, Momentum Breakout, and R", "url": "https://news.stocktradersdaily.com/news_release/43/CSBR_Volatility_Zones_as_Tactical_Triggers_070226053801_1783028281.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T17:38:00", "published_display": "02 Jul 2026 17:38", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Champions Oncology, Inc. \u2013 NASDAQ:CSBR", "summary": "This article provides the enterprise value to revenue forward for Champions Oncology, Inc. (NASDAQ:CSBR). It appears to be a financial data point presented on the TradingView platform, with information on market data providers and copyright notices. The content primarily consists", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:09:33", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight", "summary": "The global oncology-based in-vivo CRO market is projected to reach USD 3.2 billion by 2034, growing at a CAGR of approximately 8%, driven by the rising cancer burden, increasing R&D outsourcing, and advancements in animal models. North America currently leads the market, but the ", "url": "https://aijourn.com/global-oncology-based-in-vivo-cro-market-to-accelerate-substantially-at-a-cagr-of-8-by-2034-delveinsight/", "source_name": "The AI Journal", "published_at": "2026-07-01T15:09:33", "published_display": "01 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Champions Oncology, Inc. \u2013 NASDAQ:CSBR", "summary": "This article provides financial information for Champions Oncology, Inc. (NASDAQ: CSBR), specifically focusing on its price-to-sales forward ratio. It indicates that the market was closed at the time of publication, with no trades reported. The content is primarily a data placeho", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:56", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Champions Oncology, Inc. \u2013 FWB:2I3", "summary": "This article provides financial information for Champions Oncology, Inc. (FWB:2I3) listed on the Frankfurt Stock Exchange, specifically focusing on its price-to-book forward ratio. It seems to be an excerpt from a financial data platform, indicating the period, value, and change ", "url": "https://www.tradingview.com/symbols/FWB-2I3/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:42", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Champions Oncology, Inc. \u2013 NASDAQ:CSBR", "summary": "The article focuses on the \"Price to earnings forward\" metric for Champions Oncology, Inc. (NASDAQ: CSBR). It provides a brief overview of the company's financial data on the TradingView platform, indicating that the market is currently closed with no trades. The content highligh", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:11:27", "published_display": "26 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Champions Oncology, Inc. \u2013 FWB:2I3", "summary": "This article provides financial information for Champions Oncology, Inc. (FWB:2I3) regarding its Price to Earnings forward. The data is available on the TradingView platform, which sources market and reference data from ICE Data Services and FactSet, respectively. The article emp", "url": "https://www.tradingview.com/symbols/FWB-2I3/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:56", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Champions Oncology, Inc. \u2013 FWB:2I3", "summary": "This article displays the enterprise value to EBITDA forward for Champions Oncology, Inc. (FWB:2I3) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades recorded for this specific financial metric. The content primarily focuses on the f", "url": "https://www.tradingview.com/symbols/FWB-2I3/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:00", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR)", "summary": "This article provides an overview of Champions Oncology, Inc. (NASDAQ: CSBR) stock, including its current price, market capitalization, and historical performance. It also details financial estimates and actuals, highlighting revenue, earnings per share, and upcoming earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:00", "published_display": "25 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Champions Oncology Inc (CSBR) has a risk assessment score of 3.34, placing it 138th out of 387 in the Biotechnology & Medical Research industry. The company's beta of 0.40 indicates lower volatility compared to the S&P 500. The report details various risk metrics including maximu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-22T08:39:56", "published_display": "22 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Champions Oncology Inc (CSBR) currently holds a financial score of 8.65, placing it 37th out of 387 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% ye", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/financial-health", "source_name": "TradingKey", "published_at": "2026-06-21T09:11:16", "published_display": "21 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Champions Oncology Inc (CSBR), highlighting its current valuation score of 8.91 within the Biotechnology & Medical Research industry. It notes that the company's P/E ratio is -36.64, which is significantly below its recent high and ab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T06:09:49", "published_display": "19 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Champions Oncology Inc (CSBR), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, CSBR had a price momentum score of 7.27, trading between re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/technical", "source_name": "TradingKey", "published_at": "2026-06-19T01:10:27", "published_display": "19 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Institutional Confidence", "summary": "Champions Oncology Inc (CSBR) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 47.97%, marking a 7.89% decrease quarter-over-quarter. James Simons is the lar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:28", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Champions Oncology Inc (CSBR) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.15. Analysts have set a price target of $12.00 for CSBR. The company's expected revenue for the next quarter is $12.89 million, and its EPS fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:27", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Champions Oncology Inc (CSBR). It notes that the company has distributed $0.00 in dividends over the past five years and shows no recorded data for past stock splits. The article also includes current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:49", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Champions Oncology Inc (CSBR), outlining its major shareholders and institutional holdings. It provides a breakdown of individual and corporate shareholders, their proportions, and a historical view of institutional shareholding o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:49", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Champions Oncology Inc (CSBR), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for FY2026Q3, FY2026Q2, FY2026Q1, and FY2025Q3 have not yet been disclosed by the company, but does s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:59", "published_display": "17 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis of Champions Oncology Inc (CSBR), indicating a \"Strong Sell\" consensus based on various technical indicators and moving averages. Key metrics like MACD, RSI, and moving averages suggest bearish momentum, with the stock trading below its ", "url": "https://intellectia.ai/en/stock/CSBR/technical", "source_name": "Intellectia AI", "published_at": "2026-06-03T06:09:10", "published_display": "03 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR - Champions Oncology Inc Stock Price and Quote", "summary": "This article provides a detailed overview of Champions Oncology Inc (CSBR) stock, including its latest price, financial metrics, analyst ratings, and recent news and events. It lists key financial data such as market cap, income, sales, and various ratios, alongside insider owner", "url": "https://finviz.com/stock?t=CSBR", "source_name": "Finviz", "published_at": "2026-06-02T11:09:33", "published_display": "02 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc. (CSBR) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Edges Higher - Guidance Downgrade Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQX2w5UlgydHVlbWRYM2NMV2lZWWR3Vnhiclhldi0zUlpSX0xBbkJUaDhBeFJvZlA0U2MtS2pMb2JzcTZDSThJNWg1dkFDeV9TdXBsMlZBTXRNZERYSnhKY21XYjI4d1VZUXp6QTA4SDJmN2Jva1ByQ0g0R29ZTTRVRXhfUWFHblZnbklMTmpEcHdLWnlHbFJRR3dXajhrQnk4ZVE1NU94dEpQSnQwODlFdEdwWGZXcHV4U0tZWndwNjhkUjZwOEtsRzNFT3FpcjhIOFE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology (CSBR) Gains 1.59% as Stock Approaches Key Resistance Level - Ending Diagonal", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQa19mcmdFQjVwUG9LdU5IZkhDejJWNTlUeC1hdHlwZ1kyQ1l6UTc5M0pBVU85NEN2NXFXYjRHRkJscldjVGx2OFVaejQ3ZkJ5RmxFN0F3aGhkcjFlZWZEMHpaSDhTc3RkeVNjSEFoOVEwRlRyQlBqTnJHZkxobWNyTGcxVEZFMVpLMEFMTjEyMVJEZk1fNnEzODJCakMtOGltYVlNYU5BRkFZaFlnc0ptc0dKbk00X0U?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rob Brainin appointed CEO of Champions Oncology", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1kY3NheWNIWlBWSmh5MnR4QWFZTGFpMFJTampwOGRtMjg4Qy1IUzNIV0UtalRDamNKRkQzNnQ2eG5wZmRzbldJbVJQT20zOEd6YnJ6LThKcWtLQQ?oc=5", "source_name": "The Cancer Letter", "published_at": "2025-07-25T07:00:00+00:00", "published_display": "25 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BGI Americas partners with Champions Oncology to offer", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxNbVJnTmd2MWlUclFNUmxJOWpiX2VaTmVEeDh1b0IyRW5qM29EYl9pcTQ0R0JYaVJOc1JQM2dxaTVOZ3lhMUtfR2xNa2FwMkt0bnpRa05rRWpBVDBJbWxtQk9BUTV1d2Vxbkp0VVJuVHVydWhkbWkybGR0QUs1N1N0dmV1dlZ3MDlnclh3dmhjVXhkUGJObENMZDM5NHg4VGRkNHdfazhyR18zTkVuMTN1MVpGWTVLdXZ1OVdhOHZ4UEJ6YjE2dFRvVWR3b3R4N3A3d1BJSTJhTkVwN3BFN1EyUU5lc0dEUVk0Smw5dVV2ekxsc3A1V1FZYzdKc1RCLW5KRU9yV3FjaDkzZnBTZEFJYmtuV0JyRG5GWG53N1hVeXRDZGlPSDN3?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-06-15T07:00:00+00:00", "published_display": "15 Jun 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Stock Price Forecast. Should You Buy CSBR?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE9pSlZLLTFQUVpDSklhbzdHQ1d3Y0Q4U1hLczE3YVRYd1Uzc0RqMWhWZENEQmlHNXZzVlF6STVSNnlaSk5DeEg3Xw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-04T08:21:02+00:00", "published_display": "04 Dec 2020 08:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology (CSBR) Earnings Date and Reports 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1tZnJvYTFFNl94RGFoYXJGeEw5OVZkbUhHTURXTl9QVVNKY3l1Q1N2NC0zcFJKUWNTWWdLMU1XblpBR1lvMzRuRk9aR1pfcVVLTFk0bTVCeGsxVWJ3ZnpkSS1yM1VMdw?oc=5", "source_name": "MarketBeat", "published_at": "2018-06-21T18:02:39+00:00", "published_display": "21 Jun 2018 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR Stock Price and Chart \u2014 NASDAQ:CSBR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5vRDJXS2o3cHpMeU5JZHVmeTVuMkJmM2N0TklXSVlRQ0ZTSExrV05sa3RUalpGNGlrWlk5MThGWnd0QlZsUmZzSXpkX3NTbmxKRlFMUVpXTUtRVnRm?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:27:37+00:00", "published_display": "21 Jul 2017 03:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Champions Oncology to announce Q4 and FY26 results on July 27", "summary": "Champions Oncology, Inc. will release its financial and operational results for the quarter and fiscal year ended April 30, 2026, after market close on Monday, July 27, 2026. The company will also host a conference call on the same day at 4:30 P.M. ET to discuss these results. Re", "url": "https://scanx.trade/stock-market-news/companies/champions-oncology-to-announce-q4-and-fy26-results-on-july-27/46126275", "source_name": "scanx.trade", "published_at": "2026-07-21T05:40:09", "published_display": "21 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxNRk1yY2pGbk5JNEhoazNSX20zVjI5aklBQXo4RUFIdDc3ZENGVGxMMlgyX0hXTHROSmpPOE1uVmNqYkw5ekdqSEh5R2U0emZuZ1kwN2lMek9ObENabU1LenhBTFk4a0pZelctbGVzRklQNGFPTjdXcVp3ZE5MU2xna2RPbXg3UjZZanlMQ2tOUDNPQVdCYjVyZGNGa1FSZHNKRHFHa04tUEV3Nm45OWV4MG5GdFdLQVJCd096MVB4eVpfVlFaR1NlMktvcElUb1VZcHkyVFhuZFlNdkhQRWIteEZlMTdZM1A0RHlqTFdpWmVzQ0QwYjFHbUVPcXNhOGtIbXdWSEVscnlmMl83Qk5vMEcwNA?oc=5", "source_name": "Hastings Tribune", "published_at": "2026-07-20T20:32:04+00:00", "published_display": "20 Jul 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Schedules Year-End Results Call for 4:30 p.m.", "summary": "Champions Oncology (NASDAQ: CSBR) announced it will report its financial and operational results for the fourth quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call on the same day at 4:30 P.M. ET to discuss ", "url": "https://www.stocktitan.net/news/CSBR/champions-oncology-to-announce-fourth-quarter-and-year-end-financial-o13dpnuyz99h.html", "source_name": "Stock Titan", "published_at": "2026-07-20T20:40:09", "published_display": "20 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Champions Oncology, Inc. \u2013 SWB:2I3", "summary": "This article from TradingView provides financial information for Champions Oncology, Inc. (SWB:2I3), specifically focusing on its enterprise value to EBITDA forward. It indicates that the company is listed on the Stuttgart Stock Exchange and presents various financial metrics and", "url": "https://www.tradingview.com/symbols/SWB-2I3/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T06:41:04", "published_display": "19 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38 - Volatility Stop", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM09pVEVLa242bmNFQTY3dTd1enc5MlNoRjFnWnlLRUEyYzFFNkZ5bUNKYUtOZU5VdkpWSGY2U1NDRWpVR2dmaEJYWHNya1ZrRGtYNWtWTkM1R3VQTTJuZEJkX3BQYkRadnA3c2xoUHA4ejVhLVpCN2dLTWdvN1hVN2h1V2ZHZFdSRWVFVmVLODU1SU5qRE9GbGY4YUlWYU5qeVBkSHkzQlpPVzJrRWx1dFNR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-15T13:34:38+00:00", "published_display": "15 Jul 2026 13:34", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Champions Oncology, Inc. \u2013 DUS:2I3", "summary": "The article focuses on the \"Enterprise value to EBITDA forward\" metric for Champions Oncology, Inc. (DUS:2I3) listed on the Dusseldorf Stock Exchange. It appears to be a financial data point provided by TradingView, without presenting any specific values or detailed financial ana", "url": "https://www.tradingview.com/symbols/DUS-2I3/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T20:16:52", "published_display": "14 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Champions Oncology, Inc. \u2013 DUS:2I3", "summary": "This article focuses on the enterprise value to EBIT forward for Champions Oncology, Inc. (DUS:2I3) as listed on the Dusseldorf Stock Exchange. It appears to be a financial data point from a trading platform, indicating market closed with no trades. The content primarily lists va", "url": "https://www.tradingview.com/symbols/DUS-2I3/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T22:10:30", "published_display": "13 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (CSBR) Edition", "summary": "This article analyzes Champions Oncology Inc. (NASDAQ: CSBR), highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies\u2014Position", "url": "https://news.stocktradersdaily.com/news_release/39/Trading_the_Move,_Not_the_Narrative:_CSBR_Edition_071326064601_1783982761.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T18:46:00", "published_display": "13 Jul 2026 18:46", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR Q4'25 Earnings: revenue estimate is 12.89M USD", "summary": "Champions Oncology, Inc. (CSBR) is scheduled to release its Q4'25 earnings on July 16, with an estimated revenue of $12.89 million and an anticipated EPS of ($0.05). The article provides a detailed table of past and estimated revenue and EPS figures, highlighting previous surpris", "url": "https://www.tradingview.com/news/tradingview:992cc05abe7d3:0-csbr-q4-25-earnings-revenue-estimate-is-12-89m-usd/", "source_name": "TradingView", "published_at": "2026-07-09T11:12:21", "published_display": "09 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CSBR) Volatility Zones as Tactical Triggers", "summary": "Champions Oncology Inc. (NASDAQ: CSBR) is currently showing near-term weak sentiment, challenging mid-term strength within a broader long-term weak bias, according to an AI analysis. The article outlines three distinct trading strategies\u2014Position Trading, Momentum Breakout, and R", "url": "https://news.stocktradersdaily.com/news_release/43/CSBR_Volatility_Zones_as_Tactical_Triggers_070226053801_1783028281.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T17:38:00", "published_display": "02 Jul 2026 17:38", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Champions Oncology, Inc. \u2013 NASDAQ:CSBR", "summary": "This article provides the enterprise value to revenue forward for Champions Oncology, Inc. (NASDAQ:CSBR). It appears to be a financial data point presented on the TradingView platform, with information on market data providers and copyright notices. The content primarily consists", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:09:33", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight", "summary": "The global oncology-based in-vivo CRO market is projected to reach USD 3.2 billion by 2034, growing at a CAGR of approximately 8%, driven by the rising cancer burden, increasing R&D outsourcing, and advancements in animal models. North America currently leads the market, but the ", "url": "https://aijourn.com/global-oncology-based-in-vivo-cro-market-to-accelerate-substantially-at-a-cagr-of-8-by-2034-delveinsight/", "source_name": "The AI Journal", "published_at": "2026-07-01T15:09:33", "published_display": "01 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Champions Oncology, Inc. \u2013 NASDAQ:CSBR", "summary": "This article provides financial information for Champions Oncology, Inc. (NASDAQ: CSBR), specifically focusing on its price-to-sales forward ratio. It indicates that the market was closed at the time of publication, with no trades reported. The content is primarily a data placeho", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:56", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Champions Oncology, Inc. \u2013 FWB:2I3", "summary": "This article provides financial information for Champions Oncology, Inc. (FWB:2I3) listed on the Frankfurt Stock Exchange, specifically focusing on its price-to-book forward ratio. It seems to be an excerpt from a financial data platform, indicating the period, value, and change ", "url": "https://www.tradingview.com/symbols/FWB-2I3/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:42", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Champions Oncology, Inc. \u2013 NASDAQ:CSBR", "summary": "The article focuses on the \"Price to earnings forward\" metric for Champions Oncology, Inc. (NASDAQ: CSBR). It provides a brief overview of the company's financial data on the TradingView platform, indicating that the market is currently closed with no trades. The content highligh", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:11:27", "published_display": "26 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Champions Oncology, Inc. \u2013 FWB:2I3", "summary": "This article provides financial information for Champions Oncology, Inc. (FWB:2I3) regarding its Price to Earnings forward. The data is available on the TradingView platform, which sources market and reference data from ICE Data Services and FactSet, respectively. The article emp", "url": "https://www.tradingview.com/symbols/FWB-2I3/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:56", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Champions Oncology, Inc. \u2013 FWB:2I3", "summary": "This article displays the enterprise value to EBITDA forward for Champions Oncology, Inc. (FWB:2I3) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades recorded for this specific financial metric. The content primarily focuses on the f", "url": "https://www.tradingview.com/symbols/FWB-2I3/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:00", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR)", "summary": "This article provides an overview of Champions Oncology, Inc. (NASDAQ: CSBR) stock, including its current price, market capitalization, and historical performance. It also details financial estimates and actuals, highlighting revenue, earnings per share, and upcoming earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-CSBR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:00", "published_display": "25 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Champions Oncology Inc (CSBR) has a risk assessment score of 3.34, placing it 138th out of 387 in the Biotechnology & Medical Research industry. The company's beta of 0.40 indicates lower volatility compared to the S&P 500. The report details various risk metrics including maximu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-22T08:39:56", "published_display": "22 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Champions Oncology Inc (CSBR) currently holds a financial score of 8.65, placing it 37th out of 387 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% ye", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/financial-health", "source_name": "TradingKey", "published_at": "2026-06-21T09:11:16", "published_display": "21 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Champions Oncology Inc (CSBR), highlighting its current valuation score of 8.91 within the Biotechnology & Medical Research industry. It notes that the company's P/E ratio is -36.64, which is significantly below its recent high and ab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T06:09:49", "published_display": "19 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Champions Oncology Inc (CSBR), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, CSBR had a price momentum score of 7.27, trading between re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/technical", "source_name": "TradingKey", "published_at": "2026-06-19T01:10:27", "published_display": "19 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Institutional Confidence", "summary": "Champions Oncology Inc (CSBR) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 47.97%, marking a 7.89% decrease quarter-over-quarter. James Simons is the lar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:28", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Champions Oncology Inc (CSBR) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.15. Analysts have set a price target of $12.00 for CSBR. The company's expected revenue for the next quarter is $12.89 million, and its EPS fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:27", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Champions Oncology Inc (CSBR). It notes that the company has distributed $0.00 in dividends over the past five years and shows no recorded data for past stock splits. The article also includes current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:49", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Champions Oncology Inc (CSBR), outlining its major shareholders and institutional holdings. It provides a breakdown of individual and corporate shareholders, their proportions, and a historical view of institutional shareholding o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:49", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Champions Oncology Inc (CSBR), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for FY2026Q3, FY2026Q2, FY2026Q1, and FY2025Q3 have not yet been disclosed by the company, but does s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-csbr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:59", "published_display": "17 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis of Champions Oncology Inc (CSBR), indicating a \"Strong Sell\" consensus based on various technical indicators and moving averages. Key metrics like MACD, RSI, and moving averages suggest bearish momentum, with the stock trading below its ", "url": "https://intellectia.ai/en/stock/CSBR/technical", "source_name": "Intellectia AI", "published_at": "2026-06-03T06:09:10", "published_display": "03 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR - Champions Oncology Inc Stock Price and Quote", "summary": "This article provides a detailed overview of Champions Oncology Inc (CSBR) stock, including its latest price, financial metrics, analyst ratings, and recent news and events. It lists key financial data such as market cap, income, sales, and various ratios, alongside insider owner", "url": "https://finviz.com/stock?t=CSBR", "source_name": "Finviz", "published_at": "2026-06-02T11:09:33", "published_display": "02 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Inc. (CSBR) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Edges Higher - Guidance Downgrade Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQX2w5UlgydHVlbWRYM2NMV2lZWWR3Vnhiclhldi0zUlpSX0xBbkJUaDhBeFJvZlA0U2MtS2pMb2JzcTZDSThJNWg1dkFDeV9TdXBsMlZBTXRNZERYSnhKY21XYjI4d1VZUXp6QTA4SDJmN2Jva1ByQ0g0R29ZTTRVRXhfUWFHblZnbklMTmpEcHdLWnlHbFJRR3dXajhrQnk4ZVE1NU94dEpQSnQwODlFdEdwWGZXcHV4U0tZWndwNjhkUjZwOEtsRzNFT3FpcjhIOFE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology (CSBR) Gains 1.59% as Stock Approaches Key Resistance Level - Ending Diagonal", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQa19mcmdFQjVwUG9LdU5IZkhDejJWNTlUeC1hdHlwZ1kyQ1l6UTc5M0pBVU85NEN2NXFXYjRHRkJscldjVGx2OFVaejQ3ZkJ5RmxFN0F3aGhkcjFlZWZEMHpaSDhTc3RkeVNjSEFoOVEwRlRyQlBqTnJHZkxobWNyTGcxVEZFMVpLMEFMTjEyMVJEZk1fNnEzODJCakMtOGltYVlNYU5BRkFZaFlnc0ptc0dKbk00X0U?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rob Brainin appointed CEO of Champions Oncology", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1kY3NheWNIWlBWSmh5MnR4QWFZTGFpMFJTampwOGRtMjg4Qy1IUzNIV0UtalRDamNKRkQzNnQ2eG5wZmRzbldJbVJQT20zOEd6YnJ6LThKcWtLQQ?oc=5", "source_name": "The Cancer Letter", "published_at": "2025-07-25T07:00:00+00:00", "published_display": "25 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BGI Americas partners with Champions Oncology to offer", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxNbVJnTmd2MWlUclFNUmxJOWpiX2VaTmVEeDh1b0IyRW5qM29EYl9pcTQ0R0JYaVJOc1JQM2dxaTVOZ3lhMUtfR2xNa2FwMkt0bnpRa05rRWpBVDBJbWxtQk9BUTV1d2Vxbkp0VVJuVHVydWhkbWkybGR0QUs1N1N0dmV1dlZ3MDlnclh3dmhjVXhkUGJObENMZDM5NHg4VGRkNHdfazhyR18zTkVuMTN1MVpGWTVLdXZ1OVdhOHZ4UEJ6YjE2dFRvVWR3b3R4N3A3d1BJSTJhTkVwN3BFN1EyUU5lc0dEUVk0Smw5dVV2ekxsc3A1V1FZYzdKc1RCLW5KRU9yV3FjaDkzZnBTZEFJYmtuV0JyRG5GWG53N1hVeXRDZGlPSDN3?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-06-15T07:00:00+00:00", "published_display": "15 Jun 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology Stock Price Forecast. Should You Buy CSBR?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE9pSlZLLTFQUVpDSklhbzdHQ1d3Y0Q4U1hLczE3YVRYd1Uzc0RqMWhWZENEQmlHNXZzVlF6STVSNnlaSk5DeEg3Xw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-04T08:21:02+00:00", "published_display": "04 Dec 2020 08:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Champions Oncology (CSBR) Earnings Date and Reports 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1tZnJvYTFFNl94RGFoYXJGeEw5OVZkbUhHTURXTl9QVVNKY3l1Q1N2NC0zcFJKUWNTWWdLMU1XblpBR1lvMzRuRk9aR1pfcVVLTFk0bTVCeGsxVWJ3ZnpkSS1yM1VMdw?oc=5", "source_name": "MarketBeat", "published_at": "2018-06-21T18:02:39+00:00", "published_display": "21 Jun 2018 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CSBR Stock Price and Chart \u2014 NASDAQ:CSBR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5vRDJXS2o3cHpMeU5JZHVmeTVuMkJmM2N0TklXSVlRQ0ZTSExrV05sa3RUalpGNGlrWlk5MThGWnd0QlZsUmZzSXpkX3NTbmxKRlFMUVpXTUtRVnRm?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:27:37+00:00", "published_display": "21 Jul 2017 03:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 45, "sentiment_summary": {"positive": 5, "negative": 10, "neutral": 30, "score": 48, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 10.86, "count": 22}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 6.13, "latest_week": "2026-07-17", "one_week_move": 5.3, "four_week_move": -3.0, "twelve_week_move": 4.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.531996, "market_dynamics_buy_signal": false, "relative_strength": -14.156687, "fair_value_gap": -2.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.3129, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.3% over one week, -3.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 13}, {"label": "TradingKey", "count": 9}, {"label": "Market source", "count": 6}, {"label": "dars.gov.et", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "scanx.trade", "count": 1}, {"label": "Hastings Tribune", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 22}, {"label": "Market update", "count": 20}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.3% over one week, -3.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Champions Oncology to announce Q4 and FY26 results on July 27"}], "updated_at": "2026-07-22T04:14:15.269946+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}